Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) Director Jill M. Quigley sold 6,240 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $5.72, for a total transaction of $35,692.80. Following the transaction, the director now owns 8,760 shares in the company, valued at approximately $50,107.20. This trade represents a 41.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Jill M. Quigley also recently made the following trade(s):
- On Monday, January 6th, Jill M. Quigley sold 8,760 shares of Terns Pharmaceuticals stock. The stock was sold at an average price of $5.79, for a total transaction of $50,720.40.
Terns Pharmaceuticals Stock Down 0.7 %
NASDAQ TERN traded down $0.04 during trading hours on Monday, hitting $5.71. 1,252,259 shares of the stock were exchanged, compared to its average volume of 1,424,849. The company has a market cap of $485.00 million, a price-to-earnings ratio of -4.84 and a beta of -0.31. Terns Pharmaceuticals, Inc. has a 12-month low of $4.32 and a 12-month high of $11.40. The stock has a 50-day moving average of $6.35 and a 200 day moving average of $7.41.
Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.05. On average, equities research analysts expect that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on TERN. HC Wainwright reaffirmed a "neutral" rating and issued a $7.50 target price on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th. BMO Capital Markets restated an "outperform" rating and issued a $26.00 price target (up previously from $19.00) on shares of Terns Pharmaceuticals in a research report on Monday, September 16th. Oppenheimer increased their price objective on Terns Pharmaceuticals from $17.00 to $20.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 4th. Finally, JMP Securities reissued a "market outperform" rating and issued a $20.00 target price on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $18.30.
Get Our Latest Analysis on Terns Pharmaceuticals
Institutional Investors Weigh In On Terns Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. nVerses Capital LLC acquired a new position in shares of Terns Pharmaceuticals during the 3rd quarter worth $48,000. Sio Capital Management LLC purchased a new stake in Terns Pharmaceuticals during the third quarter worth about $83,000. Entropy Technologies LP acquired a new position in Terns Pharmaceuticals during the third quarter worth about $106,000. Bleakley Financial Group LLC increased its holdings in Terns Pharmaceuticals by 26.0% in the third quarter. Bleakley Financial Group LLC now owns 13,312 shares of the company's stock valued at $111,000 after buying an additional 2,751 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Terns Pharmaceuticals by 78.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,535 shares of the company's stock valued at $113,000 after acquiring an additional 5,935 shares during the period. Institutional investors and hedge funds own 98.26% of the company's stock.
About Terns Pharmaceuticals
(
Get Free Report)
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Terns Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.
While Terns Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
